Developers Finding Success Of Injectable Drugs Dependent On Numerous Factors -Analysis Trends And Prospects For Six Key Drug Classes
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Medical Devices / Diagnostics
Article Date: 08 May 2008 - 2:00 PDT
| Patient / Public: | ![]() |
1 (1 votes) |
| Healthcare Prof: | ![]() |
2 (1 votes) |
Technology has a way of providing benefits that create complexities, a lesson that drug developers and their supply chain partners are learning to deal with. Historically, the success of new drugs has focused on tolerability, safety, and pharmacokinetics. The challenges of biologically-derived drugs have added new requirements to successful drug development. Because of their far-reaching physiological effects, environmental instability and limited half-lives, recombinant drugs are pushing drug technology in a number of areas including formulation science, packaging, and delivery.
The formulation of biologics is testing the limits of drug development. The use of polymers to stabilize protein and peptide drugs is growing, and advances in drying and reconstitution are providing new options. For drugs designed to be administered by the patient, therapy-specific packaging is improving compliance and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges is improving ease-of-use and increasing the alternative device share of the growing self-injection market.
In terms of market value, most of the current demand in injectable drugs can be traced to six drug classes. For companies competing in these drug sectors, the stakes are significant and the cost of failure prohibitive. These drugs had total world sales of about $40 billion in 2007. As biological drugs currently in late-stage development become commercialized, the importance of injectable drugs to company business performance will grow considerably.
These findings are contained in a comprehensive report, researched and prepared by Greystone Associates. More information is available at http://www.greystoneassociates.org.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Greystone Associates
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/106733.php>
APA
http://www.medicalnewstoday.com/releases/106733.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




